IL102490A0 - Production of antibodies - Google Patents

Production of antibodies

Info

Publication number
IL102490A0
IL102490A0 IL102490A IL10249092A IL102490A0 IL 102490 A0 IL102490 A0 IL 102490A0 IL 102490 A IL102490 A IL 102490A IL 10249092 A IL10249092 A IL 10249092A IL 102490 A0 IL102490 A0 IL 102490A0
Authority
IL
Israel
Prior art keywords
antibodies
production
same
recombinant
prophylaxis
Prior art date
Application number
IL102490A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL102490(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919115284A external-priority patent/GB9115284D0/en
Priority claimed from GB919116594A external-priority patent/GB9116594D0/en
Priority claimed from GB929206284A external-priority patent/GB9206284D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IL102490A0 publication Critical patent/IL102490A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/106—Picornaviridae (F), e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL102490A 1991-07-15 1992-07-14 Production of antibodies IL102490A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919115284A GB9115284D0 (en) 1991-07-15 1991-07-15 Production of antibodies
GB919116594A GB9116594D0 (en) 1991-08-01 1991-08-01 Production of antibodies
GB929206284A GB9206284D0 (en) 1992-03-23 1992-03-23 Production of antibodies

Publications (1)

Publication Number Publication Date
IL102490A0 true IL102490A0 (en) 1993-01-14

Family

ID=27265765

Family Applications (1)

Application Number Title Priority Date Filing Date
IL102490A IL102490A0 (en) 1991-07-15 1992-07-14 Production of antibodies

Country Status (16)

Country Link
US (1) US5876961A (fr)
EP (1) EP0523949B1 (fr)
JP (1) JP3502093B2 (fr)
KR (1) KR100255717B1 (fr)
AT (1) ATE243747T1 (fr)
AU (1) AU662752B2 (fr)
CA (1) CA2111858A1 (fr)
DE (1) DE69233104T2 (fr)
ES (1) ES2199216T3 (fr)
FI (1) FI940144L (fr)
HU (1) HU220355B (fr)
IE (1) IE922287A1 (fr)
IL (1) IL102490A0 (fr)
NZ (1) NZ243558A (fr)
TW (1) TW373023B (fr)
WO (1) WO1993002190A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2196002T3 (es) * 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US20020122807A1 (en) * 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
ATE320450T1 (de) 2000-12-05 2006-04-15 Alexion Pharma Inc Rationell entworfene antikörper
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8658773B2 (en) * 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (fr) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Banque de fab pour la preparation de fab anti-vegf et antirabique
EP1737971B1 (fr) 2004-01-20 2017-08-16 Merus N.V. Mélanges de proteines de liason
ES2563491T3 (es) 2004-07-06 2016-03-15 Bioren, LLC Bibliotecas universales de anticuerpos
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
US8680235B2 (en) 2006-09-22 2014-03-25 Stowers Institute For Medical Research Branchiostoma derived fluorescent proteins
EP2098536A1 (fr) 2008-03-05 2009-09-09 4-Antibody AG Isolation et identification de protéines de liaison spécifiques à des antigènes ou à des ligands
JP2012508584A (ja) 2008-11-14 2012-04-12 ヴィアサイト，インコーポレイテッド ヒト多能性幹細胞由来膵臓細胞のカプセル化
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
US8293483B2 (en) * 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
US10585098B2 (en) 2009-11-23 2020-03-10 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
WO2011063395A2 (fr) * 2009-11-23 2011-05-26 The Johns Hopkins University Dispositif de flux latéral destiné au diagnostic d'infections microbiennes
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
WO2013176754A1 (fr) 2012-05-24 2013-11-28 Abbvie Inc. Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
JP6205175B2 (ja) * 2013-05-16 2017-10-04 株式会社Ｒｅｓｖｏ 精神・神経疾患バイオマーカー
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10107822B2 (en) 2013-12-16 2018-10-23 The Johns Hopkins University Interferon-gamma release assays for diagnosis of invasive fungal infections
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
WO2015130173A1 (fr) 2014-02-28 2015-09-03 Merus B.V. Anticorps qui se lie à erbb-2 et erbb-3
US9914777B2 (en) 2015-07-10 2018-03-13 Merus N.V. Human CD3 binding antibody
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
JP7230819B2 (ja) 2017-10-06 2023-03-01 小野薬品工業株式会社 二重特異性抗体
TWI890481B (zh) 2018-02-09 2025-07-11 日商小野藥品工業股份有限公司 雙特異性抗體
TWI862565B (zh) 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
TW202118790A (zh) 2019-07-30 2021-05-16 日商小野藥品工業股份有限公司 雙特異性抗體
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
TW202417488A (zh) 2022-08-23 2024-05-01 日商小野藥品工業股份有限公司 雙特異性抗體

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296024A (en) * 1974-12-09 1981-10-20 Merck & Co., Inc. Human immune serum globulin with high hepatitis A antibody titer
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
JPS6054687A (ja) * 1983-07-19 1985-03-29 スロ−ン−ケツタリング　インステイテユ−ト　フオ−　キヤンサ−　リサ−チ ヒト　モノクロ−ン抗体の製法
US4777245A (en) * 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
AU2083688A (en) * 1987-07-09 1989-02-13 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Preparation of human monoclonal antibodies of selected specificity and isotypes
FI884924L (fi) * 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
IE64966B1 (en) * 1988-10-19 1995-09-20 Dow Chemical Co A novel family of high affinity modified antibodies for cancer treatment
DE3921211C1 (fr) * 1989-06-28 1990-11-29 Idt Ag Fuer In Vivo Diagnostik Und Therapie, Zuerich, Ch
CA2066720A1 (fr) 1989-09-19 1991-03-20 David M. Knight Methode d'amelioration de la production d'anticorps monoclonaux humains
GB8925590D0 (en) * 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
ES2225816T5 (es) * 1990-02-01 2014-08-21 Siemens Healthcare Diagnostics Products Gmbh Producción y utilización de bancos de genes de anticuerpos humanos ("bibliotecas de anticuerpos humanos")
DE4002897A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
ES2196002T3 (es) * 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.

Also Published As

Publication number Publication date
CA2111858A1 (fr) 1993-02-04
DE69233104T2 (de) 2004-05-13
KR100255717B1 (ko) 2000-05-01
JP3502093B2 (ja) 2004-03-02
FI940144A0 (fi) 1994-01-12
FI940144A7 (fi) 1994-01-12
ES2199216T3 (es) 2004-02-16
DE69233104D1 (de) 2003-07-31
US5876961A (en) 1999-03-02
IE922287A1 (en) 1993-01-27
EP0523949A1 (fr) 1993-01-20
WO1993002190A1 (fr) 1993-02-04
NZ243558A (en) 1994-06-27
JPH07502882A (ja) 1995-03-30
ATE243747T1 (de) 2003-07-15
FI940144L (fi) 1994-01-12
HU220355B (hu) 2001-12-28
EP0523949B1 (fr) 2003-06-25
HU9400110D0 (en) 1994-05-30
AU2279892A (en) 1993-02-23
HUT69798A (en) 1995-09-28
AU662752B2 (en) 1995-09-14
TW373023B (en) 1999-11-01

Similar Documents

Publication Publication Date Title
HU9400110D0 (en) Production of antibodies
SG52690A1 (en) Process for the production of biologically active protein (e.g. tgf)
CZ44195A3 (en) Pharmaceutical preparation containing il-4 and/or il-10 or antibodies against il-4 and il-10, process of its preparation and use
AU2118488A (en) Improvements in or relating to methods of treating damaged skin
HUT47553A (en) Process for producing azitromycin and analogues and pharmaceutical compositions containing them as active components
EP0275005A3 (en) Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
CA2119562A1 (fr) Methode et dispositif de traitement de la paralysie cerebrale
DK0791571T3 (da) Benzoylderivater
PL308356A1 (en) Ranithidine containing compositions
EP0146266A3 (en) Enzyme-resistant immunomodulatory peptides
ZA928162B (en) Antibodies in immunosuppression.
GR79989B (fr)
IL90446A0 (en) Zinc-compatible silica for dentrifices,processes for the preparation thereof and dentrifices containing the same
CA2120153A1 (fr) Immunotoxines recombinantes
FI931826A0 (fi) Foerfarande foer framstaellning av en virussaeker, hoegt renad faktor viii
EP0054330A3 (en) Dna sequences encoding the various allelic forms of mature thaumatin, and cloning vehicles comprising said dna's and their use in transforming microorganisms
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
ATE103779T1 (de) Brausekomponente und verfahren zu ihrer herstellung.
EP0227809A4 (fr) Procede et composition pour le traitement du cancer et de tumeurs non malignes.
IL72640A (en) 2,6-bis-fluoromethyl or 2-or-6-fluoromethyl-dihydropyridine-3,5-dicarboxylic acid esters,herbicidal compositions containing them and the preparation of some such compounds
AU8452791A (en) 1-phenyl-3-aryl-2-propyne-1-ones
NO961353D0 (no) Resulfurisert austenittisk rustfritt stål med forbedret bearbeidbarhet
EP0117621A3 (en) Cosmetic
IL103856A0 (en) Aminoalkyl-substituted 5,6-dihydro-dibenz(b,e)azepin-6,11-dione-11-oximes,their preparation and pharmaceutical compositions containing them
ES8300475A1 (es) Un procedimiento para la preparacion de un alergeno